UCB taps Cradle Bio to bring AI into antibody design

What the deal is

UCB struck a collaboration with Cradle to use the startup's protein design platform and AI models for antibody work. Cradle CEO Stef van Grieken said the agreement provides UCB access to the technology, and no price tag was disclosed. He also said there is potential to expand the technology. Separately, UCB intends to use what it learns from the pilot to determine if the collaboration should be widened.

Where this fits in drugmaking

Drugmakers are increasingly weaving AI into day-to-day discovery. Beyond UCB - the company behind the anti inflammation blockbuster Cimzia - Bayer AG has used Cradle's software, and H Lundbeck A/S is using it in a project aimed at improving two antibodies for neurological disorders.

Why UCB says it matters

"What we're looking for is not so much the speed question, it's an efficiency question," UCB Chief Scientific Officer Alistair Henry said. "It's being able to get to patients with a medicine that is yes, faster, but potentially better because I can eliminate more issues in my early phases of design."

Henry said UCB aims for the approach to reduce how many design iterations and experimental molecules researchers need to produce before a top candidate emerges. He added the company expects to know in roughly a year whether candidates designed or optimized with Cradle will move forward.

New tools like artificial intelligence are quietly reshaping how investors find advantage. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.

The bottom line for investors

This is a measured pilot, not a wholesale switch, but the direction is clear. UCB is testing whether AI can shave time and waste from antibody design, while peers like Bayer and Lundbeck are already in the mix. If the pilot improves efficiency, expect UCB to extend the partnership - and watch for similar tie ups across pipelines that could reshape R&D timelines and costs.

Smart investors stay curious about emerging technology to sharpen their investment edge. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.